Samil PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 3/6
Samil PharmaceuticalLtd has a total shareholder equity of ₩174.6B and total debt of ₩143.5B, which brings its debt-to-equity ratio to 82.2%. Its total assets and total liabilities are ₩384.2B and ₩209.6B respectively. Samil PharmaceuticalLtd's EBIT is ₩5.1B making its interest coverage ratio 4.2. It has cash and short-term investments of ₩4.0B.
Key information
82.2%
Debt to equity ratio
₩143.52b
Debt
| Interest coverage ratio | 4.2x |
| Cash | ₩4.00b |
| Equity | ₩174.65b |
| Total liabilities | ₩209.58b |
| Total assets | ₩384.23b |
Recent financial health updates
Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden
Jan 03
We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt
Sep 11Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?
May 24Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden
Apr 01Recent updates
Subdued Growth No Barrier To Samil Pharmaceutical Co.,Ltd (KRX:000520) With Shares Advancing 26%
Jan 07Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden
Jan 03Some Samil Pharmaceutical Co.,Ltd (KRX:000520) Shareholders Look For Exit As Shares Take 27% Pounding
Nov 18Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking
Sep 13We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt
Sep 11Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking
Jul 29Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?
May 24There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump
Mar 30Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality
Mar 21Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden
Apr 01Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment
Mar 11Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?
Feb 15
Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?
Jan 20Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend
Dec 24Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment
Dec 09What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?
Nov 18Financial Position Analysis
Short Term Liabilities: A000520's short term assets (₩87.5B) do not cover its short term liabilities (₩116.1B).
Long Term Liabilities: A000520's short term assets (₩87.5B) do not cover its long term liabilities (₩93.5B).
Debt to Equity History and Analysis
Debt Level: A000520's net debt to equity ratio (79.9%) is considered high.
Reducing Debt: A000520's debt to equity ratio has reduced from 128.6% to 82.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable A000520 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: A000520 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 19.2% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 15:07 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Samil Pharmaceutical Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sun-Jae Heo | SK Securities Co., Ltd. |